During the past decade, Summit Cancer Care-Candler conducted 39 clinical trials. In the 10-year time frame, 39 clinical trials started and 13 clinical trials were completed, i.e. on average, 33.3% percent of trials that started reached the finish line to date. In the past 5 years, 2 clinical trials started and 13 clinical trials were completed. i.e. 650% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Summit Cancer Care-Candler" #1 sponsor was "National Cancer Institute (NCI)" with 19 trials, followed by "Alliance for Clinical Trials in Oncology" with 7 trials sponsored, "SWOG Cancer Research Network" with 7 trials sponsored, "ECOG-ACRIN Cancer Research Group" with 4 trials sponsored and "NRG Oncology" with 4 trials sponsored. Other sponsors include -4 different institutions and companies that sponsored additional 6 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Summit Cancer Care-Candler" #1 collaborator was "National Cancer Institute (NCI)" with 20 trials as a collaborator, "Canadian Cancer Trials Group" with 5 trials as a collaborator, "NRG Oncology" with 2 trials as a collaborator, "Bayer" with 1 trials as a collaborator and "Division of Cancer Control" with 1 trials as a collaborator. Other collaborators include -1 different institutions and companies that were collaborators in the rest 9 trials.

According to Clinical.Site data, the most researched conditions in "Summit Cancer Care-Candler" are "Breast Carcinoma" (3 trials), "Primary Peritoneal High Grade Serous Adenocarcinoma" (3 trials), "Clinical Stage III Cutaneous Melanoma AJCC v8" (2 trials), "Clinical Stage IV Cutaneous Melanoma AJCC v8" (2 trials) and "Endometrioid Adenocarcinoma" (2 trials). Many other conditions were trialed in "Summit Cancer Care-Candler" in a lesser frequency.

Most popular intervention types in "Summit Cancer Care-Candler" are "Other" (25 trials), "Drug" (23 trials), "Biological" (18 trials), "Procedure" (16 trials) and "Radiation" (2 trials). Other intervention types were less common.

The name of intervention was led by "Computed Tomography" (12 trials), "Laboratory Biomarker Analysis" (12 trials), "Biospecimen Collection" (11 trials), "Nivolumab" (9 trials) and "Quality-of-Life Assessment" (9 trials). Other intervention names were less common.

The vast majority of trials in "Summit Cancer Care-Candler" are 34 trials for "All" genders and 5 trials for "Female" genders.

Currently, there are NaN active trials in "Summit Cancer Care-Candler". undefined are not yet recruiting, 7 are recruiting, 25 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 1 completed trials in Summit Cancer Care-Candler, 1 suspended trials, and 5 terminated clinical trials to date.

Out of the total trials that were conducted in Summit Cancer Care-Candler, 2 "Phase 1" clinical trials were conducted, 20 "Phase 2" clinical trials and 16 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 3 trials that are defined as “Not Applicable".